| 摘要 |
The present invention provides to at least one novel human GLP-I receptor agonist, or specified portion or variant, including isolated nucleic acids that encode at least one GLP-I receptor agonist, or specified portion or variant, GLP-I receptor agonist, or specified portion or variants, vectors, host cells, transgenic animals or plants, and methods of making and using thereof, including the use of long acting GLP-I receptor agonists to improve insulin sensitivity or lipid profiles in obesity and related therapeutic and/or diagnostic compositions, methods and devices. ® KIPO & WIPO 2009
|
